ImmuneSense COVID-19 Variant Study

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

July 20, 2022

Study Completion Date

July 28, 2022

Conditions
Covid19
Interventions
DEVICE

T-Detect COVID test

• The T-DetectTM COVID test is an EUA granted investigational device that is indicated to assess a T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19.

Trial Locations (15)

10001

Decentralized Clinical Trial Model- New York City, New York

20001

Decentralized Trial Model - Washington D.C., Washington D.C.

22400

Decentralized Trial Model- California, San Diego

33101

Decentralized Trial Model- Florida, Miami

80014

Decentralized Trial Model- Denver, Denver

84044

Decentralized Trial Model- Utah, Salt Lake City

85001

Decentralized Trial Model- Phoenix, Phoenix

90034

Decentralized Trial Model- California, Los Angeles

90621

Decentralized Trial Model- Fullerton, Fullerton

94016

Decentralized Trial Model- San Francisco, San Francisco

94203

Decentralized Trial Model- Sacramento, Sacramento

95313

Decentralized Trial Model- Modesto, Modesto

97035

Decentralized Trial Model- Portland, Portland

98109

Decentralized Trial Model- Seattle, Seattle

98607

Decentralized Trial Model- Vancouver, WA, Vancouver

Sponsors
All Listed Sponsors
lead

Adaptive Biotechnologies

INDUSTRY